Analytical Data
-
Gene name
CD72
- Application
-
Alternative Names
CD72; Lyb-2; Lyb2
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q5BK59
-
Expression Region
Val126~His237
-
Molecular Weight
17kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD72 is a type II transmembrane glycoprotein primarily expressed on the surface of B cells and has been implicated in the modulation of B cell activation and signaling. As a member of the immune system's regulatory network, CD72 interacts with its ligand, CD100, to influence B cell responses, and its dysregulation has been associated with various autoimmune diseases and lymphoproliferative disorders. Research on CD72 recombinant proteins has gained attention due to their potential utility in understanding the molecular mechanisms underlying B cell activation and function. By generating CD72 recombinant proteins, researchers can elucidate the role of CD72 in immune responses, explore its interactions with other proteins, and evaluate its potential as a therapeutic target. Studies using these proteins may also provide insights into the development of monoclonal antibodies or other biological agents aimed at modulating B cell activity in the context of diseases such as systemic lupus erythematosus and multiple sclerosis. Thus, the exploration of CD72 recombinant proteins is crucial for advancing our knowledge of B cell biology and developing innovative strategies for treating immune-related conditions.
